UK approves Pfizer COVID-19 vaccine for use, first in the world

CEO Albert Bourla praises emergency use authorization as 'historic moment', while hospitals in England have been told to get ready to start doing vaccinations for medical workers as early as next week

News agencies|
Britain on Wednesday became the first country in the world to approve the Pfizer-BioNTech COVID-19 vaccine for use and said that it will be rolled out from early next week.
  • Follow Ynetnews on Facebook and Twitter

  • Other countries aren't far behind: The U.S. and the European Union also are vetting the Pfizer shot along with a similar vaccine made by competitor Moderna Inc. British regulators also are considering another shot made by AstraZeneca and Oxford University.
    2 View gallery
    Pfizer COVID-19 vaccine
    Pfizer COVID-19 vaccine
    Pfizer COVID-19 vaccine
    (Photo: Reuters)
    "The Government has today accepted the recommendation from the independent Medicines and Healthcare products Regulatory Agency (MHRA) to approve Pfizer-BioNTech's COVID-19 vaccine for use," the government said. "The vaccine will be made available across the UK from next week."
    British media have reported that hospitals in England have been told to get ready to start doing vaccinations for medical workers as early as next week.
    Pfizer said it would immediately begin shipping limited supplies to the U.K. - and has been gearing up for even wider distribution if given a similar nod by the U.S. Food and Drug Administration, a decision expected as early as next week.
    2 View gallery
    אלברט בורלא מנכ"ל פייזר
    אלברט בורלא מנכ"ל פייזר
    Pfizer CEO Albert Bourla
    (Photo: AP)
    Pfizer said Britain's emergency use authorization marks a historic moment in the fight against COVID-19.
    "This authorization is a goal we have been working toward since we first declared that science will win, and we applaud the MHRA for their ability to conduct a careful assessment and take timely action to help protect the people of the U.K.," said CEO Albert Bourla.
    "As we anticipate further authorizations and approvals, we are focused on moving with the same level of urgency to safely supply a high-quality vaccine around the world."
    Doses everywhere, however, are scarce, and initial supplies will be rationed until more is manufactured in the first several months of next year.
    Comments
    The commenter agrees to the privacy policy of Ynet News and agrees not to submit comments that violate the terms of use, including incitement, libel and expressions that exceed the accepted norms of freedom of speech.
    ""